|
May 13
|
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
|
|
Apr 11
|
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
|
|
Mar 14
|
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
|
|
Mar 11
|
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
|
|
Feb 20
|
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
|
|
Dec 30
|
US Penny Stocks To Consider In December 2024
|